Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACKLE: AZD7442 (Evusheld) for Treatment of COVID-19
NCT04723394Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Jan 2021; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04723394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723394.